Sara Bonanzinga

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 06, 2024

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Journal: Hepatology communications

Published: December 06, 2022

Assessment of the cobas® HBV RNA investigational assay in the setting of nucleoside analog therapy cessation.

Assessment of the cobas® HBV RNA investigational assay in the setting of nucleoside analog therapy cessation.

Journal: Journal of medical virology

Published: June 03, 2022

Autochthonous and Travel Acquired Hepatitis E Virus in Australia.

Autochthonous and Travel Acquired Hepatitis E Virus in Australia.

Journal: Frontiers in microbiology

Published: December 11, 2020

Multicenter clinical evaluation of alinity m HCV assay performance.

Multicenter clinical evaluation of alinity m HCV assay performance.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: March 18, 2020

Multicenter clinical evaluation of alinity m HBV assay performance.

Multicenter clinical evaluation of alinity m HBV assay performance.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: March 09, 2020

The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.

The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.

Journal: Alimentary pharmacology & therapeutics

Published: January 12, 2015

ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.

ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.

Journal: Hepatology (Baltimore, Md.)

Published: November 18, 2013

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.

Journal: Journal of gastroenterology and hepatology

Published: December 21, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026